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Objective: This study aimed to evaluate the impacts of deep surgical site infections (dSSIs) 
regarding hospital readmissions, prolonged length of stay (LoS), and estimated costs.
Patients and Methods: We designed and applied a matched case–control observational 
study using the electronic health records at the University Medical Center Groningen in the 
Netherlands. We compared patients with dSSI and non-SSI, matched on the basis of having 
similar procedures. A prevailing topology of surgeries categorized as clean, clean-contami-
nated, contaminated, and dirty was applied.
Results: Out of a total of 12,285 patients, 393 dSSI were identified as cases, and 2864 patients 
without SSIs were selected as controls. A total of 343 dSSI patients (87%) and 2307 (81%) 
controls required hospital readmissions. The median LoS was 7 days (P25-P75: 2.5–14.5) for dSSI 
patients and 5 days (P25-P75: 1–9) for controls (p-value: <0.001). The estimated mean cost per 
hospital admission was €9,016 (SE±343) for dSSI patients and €5,409 (SE±120) for controls 
(p<0.001). Independent variables associated with dSSI were patient’s age ≥65 years (OR: 1.334; 
95% CI: 1.036–1.720), the use of prophylactic antibiotics (OR: 0.424; 95% CI: 0.344–0.537), 
and neoplasms (OR: 2.050; 95% CI: 1.473–2.854).
Conclusion: dSSI is associated with increased costs, prolonged LoS, and increased read-
mission rates. Elevated risks were seen for elderly patients and those with neoplasms. 
Additionally, a protective effect of prophylactic antibiotics was found.
Keywords: surgical wound infection, prophylactic antibiotic, patient admission, economic 
evaluation, cost
Introduction
Surgical site infections (SSIs) present a high risk of prolonged lengths of stay (LoS) and 
readmissions.1–5 In the United States, SSIs reportedly occurred in 1.9% of surgical 
procedures.6 These infections incur costs, ranging between US$480 and US$22,130 
per patient.7 In addition, the European Centre for Disease Prevention and Control 
(ECDC) in 2011–2012 reported that SSI was the most common healthcare-associated 
infection with an incidence of 156.5 per 100,000 population.8 Most concern exists 
about specific sites of infections, such as deep SSI (dSSI) involving infection of soft 
tissues of fascia and muscles with a high risk of development of sepsis as a 
complication.1,9 In addition, a correlation has been found between the type of surgery, 
categorized according to the prevailing typology of clean, clean-contaminated, 
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contaminated and dirty surgeries, and the risk of contracting 
an SSI.10–12 Operation procedures with clean-contaminated 
and dirty have been reported being associated with a high 
burden of dSSI.13–15
Among European countries, the Netherlands has imple-
mented an integrative stewardship program that has been 
effectively performed in many Dutch hospitals to manage 
hospital infections including dSSI. The program is applied 
for antimicrobial use, infection prevention, and diagnostic 
stewardship, involving a multidisciplinary team with infec-
tious diseases, infection control practitioners as well as clinical 
microbiologists and hospital pharmacists.16,17 From the 
ECDC 2016 and 2017 reports, SSI incidence in the 
Netherlands is shown to have decreased from 2.2 to 1.0 per 
100 surgeries, respectively.8 In general, the burden of health-
care-associated infections on the European population has 
been estimated at 501 disability-adjusted life years (DALYs) 
per 100,000 general population annually.8 In the Netherlands, 
dSSI was responsible for 3200 DALYs per year for colec-
tomies and 1200 DALYs per year for total hip arthroplasties, 
with the national financial burdens for each of these conditions 
estimated at €29 million and €10 million, respectively.18
A dSSI surveillance performed for the Netherlands 
(“PREZIES”; 1996–2004), documented dSSI rates at 3.7% 
in 93,511 surgical procedures, with the highest dSSI rate in 
the procedures of colon resections (6.7%).19,20 An evidence 
found that in contrast to superficial SSIs, dSSIs contribute an 
additional mean LoS of 2–2.6 days.21 dSSIs are considered a 
high burden in the group of hospitalization infection.21,22 To 
deal with the burden of dSSI, various modalities have been 
implemented, ranging from the use of prophylactic antibio-
tics before surgical incision to the subsequent antibiotic 
treatment of dSSI, including empiric treatment that being 
installed based on national/local guidelines.23,24 In the prac-
tical setting of the implementation of the strategies, it is 
important to assess the impacts of further dSSI complica-
tions, such as readmissions, the emergence of resistant bac-
teria, and additional costs. Here, we evaluated the impacts of 
dSSIs in terms of readmission rates, hospitalization costs, 
and LoS in a matched case–control study in an academic 
hospital in The Netherlands. In addition, we investigated 
predictors for the development of dSSI.
Patients and Methods
Patients Data
We performed a matched case–control observational study 
using the electronic health records at the University Medical 
Center Groningen (UMCG), the largest hospital in the 
Northern Netherlands, comprising of 1339 beds. We 
included patients whose surgical procedures were conducted 
between 2014 and 2016, where the data have been validated 
by the surgeon for dSSI diagnoses and by the Finance 
Department for the reimbursements. Also, the hospital 
started the surveillance for SSI began in 2014. Data on 
clinical characteristics, comorbidities, costing codes, and 
occurrence of superficial SSIs, dSSIs, and organ/space SSIs 
diagnoses of anonymized patients were collected. The infec-
tion was confirmed by the presence of purulent drainage, 
abscesses, or other evidence of local infection from deep 
soft tissues (fascial and muscles) at the incision site. 
Symptoms experienced by dSSI patients could include loca-
lized pain, tenderness, and fever (>38°C).9 A surgeon or an 
attending physician at the hospital conducted individual dSSI 
diagnoses following the ECDC criteria. The ECDC protocol 
for SSI surveillance defines a dSSI case as an infection 
acquired within 30 days of non-implant surgery or up to a 
year after implant surgery.25
We matched the surgical specializations and the surgical 
technique used in patients with dSSI and non-SSI. We categor-
ized the types of surgeries using the ECDC protocol, based on 
clean (W1), clean-contaminated (W2), contaminated (W3) and 
dirty wound surgeries (W4).25 Clean surgery is defined as a 
surgical procedure that does not involve the alimentary, 
respiratory, or genitourinary tracts. Surgical procedures that 
do not involve penetrating trauma fall under this category.25,26 
Clean-contaminated surgeries, such as appendectomies, 
hysterectomies, or surgical procedures relating to oropharyn-
geal cancer, entail entry into the alimentary, respiratory, or 
genitourinary tracts without any usual contamination.25,26 
Contaminated surgeries include coronary bypass or hip repla-
cement, where there is gross spillage during the sterile 
procedure,27 or where there is contact with gallbladder, urine, 
or the gastrointestinal lumen. Dirty or infected surgeries are 
characterized by abscesses in visceral organs or infected organs 
or tissues.26,28,29 All of the surgical procedures included in the 
study are listed in the Supplementary material.
Outcome Measurements
We considered readmission, LoS in days, and costs of 
dSSI complications in our analysis. Readmission asso-
ciated with dSSIs was defined as a subsequent admission 
within the same hospital that occurred within a 30-day 
period following the initial hospital discharge.30–32 LoS 
data was sourced directly from the hospital discharge 
records for each admission. Costs were based on the 
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method within the Dutch healthcare systems labelled “the 
Dutch diagnoses related groups (DRGs) (in Dutch: 
“Diagnose Behandeling Combinaties” [DBCs]) within 
specialized hospital care (https://www.vergelijkdezorgver 
zekeringen.nl/dbc-declaratiecode/). This is different from 
the common established DRGs that are used widely world-
wide. These groups are based upon a combination of 
treating specialty, diagnosis, and procedures and are uni-
formly scored throughout the country. We applied hospital 
reference prices of these groups for the period 
2014–2016.33–35 The World Health Organization (WHO) 
considers the use of prophylactic antibiotics as an impor-
tant measure in SSI prevention.36 We therefore addition-
ally evaluated the impacts of prophylactic antibiotics on 
the outcome of dSSIs. These antibiotics were administered 
to the patients within a period of 60 minutes prior to an 
incision being made.
Statistical Analyses
Data analyses were performed using IBM SPSS statistics 
version 25. We presented descriptive data as counts and per-
centages. Chi-square tests were applied to analyze statistical 
differences in proportions between case and control groups. 
We performed univariate and multivariate analyses of the 
cases to determine the predictors of a dSSI outcome including 
potentially relevant predictors sex, age, the use of prophylactic 
antibiotics before the initial incision, types of surgery, surgery 
sites, and comorbidities. In the multivariate logistic regression 
model, we minimized the degrees of freedom and excluded 
variables with a number of events below ten by merging age- 
related covariates into two categories (<65 vs. ≥65 years) and 
by the categorizing four types of surgery W1 through W4. In 
addition, we used Chi-square to test the goodness-of-fit of the 
logistic model. Each risk was presented as an odds ratio (OR) 
together with a 95% confidence interval (CI). The variables 
that met the criteria of the 95% CI not including 1 were 
considered significant and included in the analyses.
We assessed the impact of dSSI on the LoS outcome 
with a time to event analysis, the event being the discharge 
of the patient. First, a Kaplan-Meier test and Log Rank test 
were performed to assess the differences in LoSs, mea-
sured as the times to hospital discharge between dSSI 
patients and those in the control group within the 120- 
days time frame. Differences in mean costs were analyzed 
using a two-sided t-test. Because the data on costs were 
highly skewed, we performed bootstraps for 1000 
samples.37,38 Second, we assessed the predictors for the 
LoS outcome using a Cox-regression analysis with 
categorical backward selection on variables of having 
dSSI, sex, age, types of surgery, and comorbidities. 
Hazard ratios (HRs) lower than 1 indicated extended 
LoS, while HR higher than 1 indicated shorter LoS.39 
Statistical differences were considered significant at a 
p-value < 0.05.
Results
We examined a total of 12,285 registered patients who were 
admitted and underwent various surgical procedures 
between 2014 and 2016 in all surgical departments. Of 
those, infections were reported for 1624 (13.2%) patients 
while no infections were reported 10,661 patients (86.8%). 
An SSI rate was documented at 5.3% of the total surgical 
procedures, while dSSI was diagnosed in 393 (3.2%) that 
were included in the analyses as cases. There was no report 
of patients with organ/space SSIs. The control group com-
prised 2864 patients (23%) who fulfilled the matching cri-
teria relating to surgical procedures. The selection of the 
patients investigated in this study is shown in Figure 1.
Fifty-two percent of the patients were men with an average 
age of 52.9 (±17.9) years compared to females with a mean age 
of 51.7 (±16.9) years. Out of 393 cases and 2864 controls, 343 
(87%) and 2307 (81%) patients, respectively, were readmitted 
within 30 days of their surgical procedures. Most initial admis-
sions (32%) and readmissions (33%) concerned abdominal 
surgeries. Seventy-nine percent of patients with neoplasms 
(281 out of 356) were readmitted with neoplasms being the 
most frequently observed comorbidity (10.9%). The baseline 
characteristics of the patients are summarized in Table 1. 
Incidences of dSSI were lower among patients who received 
prophylactic antibiotics prior to undergoing surgery compared 
with such incidences among those who did not receive pro-
phylactic treatment (38% vs. 62%, respectively, p<0.001).
The median LoS for all patients was 5 days (P25-P75: 
2–10). Patients with dSSIs stayed longer in the hospital 
compared to those without SSI (Log-Rank p-value ≤0.001). 
The median LoS was 7 days (P25-P75: 2.5–14.5) for dSSI 
patients and 5 days (P25-P75: 1–9) for non-SSI patients. 
Kaplan-Meier plots of LoS differences between dSSI and 
non-SSI patients are depicted in Figure 2. Having dSSI and 
being 65 years or older were the two independent factors 
associated with prolonged LoS, with HRs of 0.742 (95% CI: 
0.679–0.809), and 0.809 (95% CI: 0.750–0.873), respec-
tively. The multivariate logistic regression model for pro-
longed LoS outcome are presented in Table 2.
The mean cost of clean surgery was €4,391 per patient, 
with respective mean costs of €5,505 and €4,247 for dSSI 
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and non-SSI patients (a difference of €1,258; p<0.001). 
The mean cost of clean-contaminated surgeries per patient 
was estimated at €6,788, with respective mean costs of 
€12,479 and €6,182 for dSSI and non-SSI patients (a 
twofold difference; p<0.001). The average hospitalization 
cost was highest for contaminated surgeries with at an 
average of €8,219 per patient, with €13,170 for dSSI and 
€7,424 for non-SSI (equivalent to 1.8 times higher; 
p<0.001). Dirty surgery showed the lowest mean cost 
(€3,027) among all types of surgical procedures. Overall, 
the average cost for all cases was €5,844 (±121) per 
patient, with respective mean costs of €9,016 (±343) and 
€5,409 (±120) for dSSI and non-SSI (cost difference of 
€3,607; p<0.001). Table 3 lists the hospitalization costs per 
patient for each type of surgery.
In the multivariate analyses, we excluded the diabetes 
mellitus covariate as the number of patients in the control 
group was too small (n=8). There were two independent vari-
ables turning out as factors for dSSI: age ≥65 (OR: 1.334; 95% 
CI: 1.036–1.720) and neoplasm (OR: 2.050; 95% CI: 1.473– 
2.854). The use of prophylactic antibiotics before the initial 
incision showed a protective effect against dSSI (OR: 0.424; 
95% CI: 0.344–0.537). The results of the univariate and multi-
variate analyses are summarized in Table 4.
Discussion
Our findings indicated that the costs, LoS and readmission 
rates of dSSI cases were higher than those of non-SSI 
cases in all types of surgeries. Clean surgeries associated 
with the head and neck, thorax, extremities, and spine 
were performed most frequently in this hospital, followed 
by contaminated and dirty surgeries in which the abdom-
inal region was commonly the targeted site. Our findings 
documented that having dSSI and being aged ≥65 were the 
two independent factors for extended LoS. Notably, 
elderly patients (≥65 years) and patients with neoplasms 
or cardiovascular diseases would have a higher risk of 
dSSI, while patients receiving prophylactic antibiotics 
would have a lower risk of dSSI. This finding supports 
enhancing developed facilities for managing infection pre-
vention procedures in the Netherlands.
The hospital under investigation has developed an inte-
grated stewardship with a theragnostic approach, which has 
been conceptualized in a multi-faceted model of antimicro-
bial (A), infection prevention (I), and diagnostic (D) stew-
ardship, labeled AID model. AID involves trained staff, 
covering diverse specialties, and is dedicated to controlling 
hospital-acquired infections and stemming further antimi-
crobial resistance.16,17,40 The dSSI rates in our study were 
documented in the range of PREZIES findings that were 
between 0.2% and 5.9% of all surgical procedures.20 In a 
systematic review, the global incidence of SSIs ranged from 
0% to 70%.7 The rates of SSI depend on the surgery types 
and locations as well as prophylactic treatment.7,41 WHO 
and ECDC also revealed that the use of prophylactic anti-
biotics prior to initial incision reflects a proper and 
Figure 1 Flow-chart depicting the process of selecting deep SSI (case) and the control.
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Table 1 Baseline Characteristics of Patients with dSSI and Non-SSI During Initial Admissions and Readmissions


















Male 1512(46.4) 202(51.4) 1310(45.7) 0.035* 1256(47.4) 183(53.4) 1073(46.5) 0.018*
Female 1745(53.6) 191(48.6) 1554(54.3) 1394(52.6) 160(46.6) 1234(53.5)
Age
<65 years 2466(75.7) 269(68.4) 2197(76.7) <0.001* 2030(76.6) 234(68.2) 1796(77.9) <0.001*
≥65 years 790(24.3) 124(31.6) 666(23.3) 620(23.4) 109(31.8) 511(22.1)
Antibiotic 
prophylaxis
No 1562(48.0) 242(61.6) 1320(46.1) <0.001* 1252(47.2) 207(60.3) 1045(45.3) <0.001*
Yes 1695(52.0) 151(38.4) 1544(53.9) 1398(52.8) 136(39.7) 1262(54.7)
Types of surgery
Clean 1571(48.2) 180(45.8) 1391(48.6) 0.329 1301(49.1) 161(46.9) 1140(49.4) 0.392
Clean- 
contaminated
572(17.6) 55(14.0) 517(18.1) 0.056 400(15.1) 46(13.4) 354(15.3) 0.351
Contaminated 940(28.9) 130(33.1) 810(28.3) 0.056 788(20.7) 109(31.8) 679(29.4) 0.375
Dirty 174(5.3) 28(7.1) 146(5.1) 0.094 161(6.1) 27(7.9) 134(5.8) 0.136
Location of surgery
Head and neck 329(10.1) 83(21.1) 246(8.6) <0.001* 308(11.6) 79(23.0) 229(9.9) <0.001*
Upper-extremity 82(2.5) 25(6.4) 57(2.0) <0.001* 57(2.2) 23(6.7) 34(1.5) <0.001*
Thorax 558(17.1) 42(10.7) 516(18.0) <0.001* 380(14.3) 28(8.2) 352(15.3) <0.001*
Abdomen 1055(32.4) 153(38.9) 902(31.5) 0.003* 865(32.6) 130(37.9) 735(85.0) 0.026*
Spine 791(24.3) 28(7.1) 763(26.6) <0.001* 672(25.4) 26(7.6) 646(28.0) <0.001*
Lower-extremity 442(13.6) 62(15.8) 380(13.3) 0.173 368(13.9) 57(16.6) 311(13.5) 0.117
Organ 
transplantation
102(3.1) 7(6.9) 95(3.30) 0.101 95(3.6) 6(1.7) 89(3.9) 0.050
Comorbidities
Neoplasm 356(10.9) 62(15.8) 294(10.3) <0.001* 281(10.6) 55(16.0) 226(9.8) 0.001*
Diabetes mellitus 20(0.6) 12(3.1) 8(0.3) <0.001* 20(0.8) 12(3.5) 8(0.3) <0.001*
Cardiovascular 
diseases
196(6.0) 12(3.1) 184(6.4) 0.011* 112(4.2) 10(2.9) 102(4.4) 0.250
Note: *Statistically significant, p <0.05.
Figure 2 Kaplan-Meier curve of the lengths-of-stay of dSSI patients and controls with non-SSIs (LogRank, p<0.001) 
Note: There was no any hospital discharge after day-82 among dSSI patients
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successful modality to decrease SSI incidence.25,42 This 
illustrates the crucial moment of the preoperative phase to 
prevent SSIs by adherence to adequate uses of prophylactic 
antibiotics relating to their selection, optimal dosing, and 
timing.7,43 Related monitoring relating of post-operative 
measures focuses on the prolonged use of prophylactic 
antibiotics and the timing of drain removal.42
Our findings show that the hospitalization cost for dSSI 
was higher compared with non-SSI. The burden of additional 
costs incurred for dSSI cases is plausibly reflected in pro-
longed hospitalization, as well as readmissions.21,44-46 As a 
comparative reference, respective SSI and non-SSI costs of 
€1,011 and €1,167 per patient day may serve as reported by a 
German hospital geographically close to the hospital in 
Groningen. The reported LoS for those patients ranged 
between 34.4 and 16.5 days with total hospitalization costs 
per SSI and non-SSI patients of €36,261 and €13,356, 
respectively.47,48 In addition to the impact of SSIs on pro-
longed LoS, a previous study in cardiac surgery showed that 
SSIs evidently had a significant impact on LoS and costs as 
indicated by 3.8-fold and 5.8 fold increases, respectively, as 
compared with these measures for non-SSI patients.49
Approximately 87% of dSSI patients in the present 
study were readmitted compared with 81% of non-SSI 
patients. Readmissions were often due to the presence of 
comorbidities such as neoplasm, diabetes, and cardiovas-
cular diseases. Evidently, readmission contributes to high 
costs. Wick et al, estimated that the cost of surgical read-
mission after colorectal surgery in the United States was 
US$8,885 per stay with a mean LoS of 8 days.50 A pre-
vious study found that more than 50% of SSI cases were 
readmitted for revision surgery because of wound infec-
tions at the surgery sites and other post-surgical complica-
tions such as bleeding, dehydration, renal failure, 
embolism, cardiovascular events, and ileus.1,3 Other stu-
dies indicate that approximately 76–97% of SSI patients 
are readmitted at least once for revision surgery or wound 
debridement.51,52 Post-surgical readmission could be sub-
stituted by performing a home visit or providing outpatient 
care within an earlier 30-day medical follow-up after sur-
gical discharge, possibly alleviating the costs. Jencks et al, 
reported that the post-surgery monitoring for infections 
effectively reduced readmission rates.53 Additionally, the 
timing of unanticipated readmissions after surgical 
Table 2 The Multivariate Logistic Regression Model for Length of Stay
Variables B SE Wald p-value HR Lower 95% CI HR Upper 95% CI HR
Having dSSI
No Ref Ref
Yes −0.299 0.045 44.683 <0.001 0.742* 0.679 0.809
Sex
Male Ref Ref
Female 0.049 0.030 2.624 0.105 1.050 0.990 1.115
Age
<65 years Ref Ref
≥65 years −0.212 0.039 29.747 <0.001 0.809* 0.750 0.873
Antibiotic prophylaxis
No Ref Ref
Yes 0.092 0.031 8.615 0.003 1.096* 1.031 1.166
Types of surgery
Clean Ref Ref
Clean-contaminated 0.015 0.046 0.112 0.738 1.016 0.928 1.112
Contaminated 0.105 0.037 8.053 0.005 1.110* 1.033 1.193
Dirty 0.291 0.069 17.600 <0.001 1.338* 1.168 1.533
Comorbidities
Neoplasm 0.187 0.045 17.328 <0.001 1.206* 1.104 1.317
Cardiovascular diseases −0.046 0.084 0.299 0.585 0.955 0.881 1.125
Notes: *Statistically significant; the 95% CI does not include a value of 1. 
Abbreviations: dSSI, deep surgical site infection; CI, confidence interval; HR, hazard ratio; Ref, reference.
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discharge, which is mainly contingent on the emergence of 
crises relating to serious complications or existing comor-
bidities, requires further investigation.1 Moreover, in our 
study, dSSI patients aged 65 years or above were signifi-
cantly at higher risk for readmissions. This finding is in 
line with that of Kaye et al, who reported that the LoS for 
hospitalization and post-surgery readmission of elderly 
patients with SSIs was three times greater than that for 
non-SSI patients. Moreover, the mean cost incurred by 
older patients was US$ 43,970, which was double the 
cost incurred by non-SSI patients.54
In clean surgeries, such as thyroidectomies, the pro-
phylactic use of antimicrobial agents is unlikely to be 
necessary.55 Reported SSI rates for clean surgeries ranged 
between 0% and 3%.14,56 The incidence of SSI in clean- 
contaminated surgeries is reported to range between 3% 
and 11%,13,14 while the SSI rate for contaminated sur-
geries is approximately 15% of all surgical procedures.14 
Additionally, a high SSI rate of at least 20% has been 
reported for laparoscopies performed in cases of perfo-
rated appendicitis, which are considered dirty surgeries.15 
In line with our findings, a previous systematic review and 
an original study reported that the risk of SSI is high for 
orthopedic and general surgery involving the thorax, abdo-
men, spine, and lower extremities.1,7 The reason for these 
findings may be that the risk of SSI is also contingent on 
the performance of individual procedures that facilitate the 
invasion of underlying pathogens. Furthermore, our find-
ings showed that the total hospitalization costs for dirty 
procedures were estimated higher compared to those for 
Table 3 Hospitalization Cost per Patient Categorized by the Types of Surgery
Costs, Mean (SE) All Cases dSSI Cases Non-SSI Cases Cost Difference p-value
Clean surgery €4,391.11(109.21) €5,505.08(321.26) €4,246.95(113.06) €1,258.13(341.41) <0.001*
Clean-contaminated surgery €6,787.76(447.29) €12,478.61(1,420.59) €6,182.34(466.91) €6,296.27(1,494.24) <0.001*
Contaminated surgery €8,218.74(231.74) €13,170.11(1,019.01) €7,424.07(200.30) €5,746.03(644.93) <0.001*
Dirty surgery €3,027.80(298.48) €5,497.86(1,027.58) €2,554.09(281.70) €2,943.76(783.10) <0.001*
Note: *Statistically significant, p <0.05. 
Abbreviation: SE, standard error.
Table 4 The Multivariate Logistic Regression Model for Deep Surgical-Site Infections
Characteristics Univariate Analysis Multivariate Analysis
Crude OR 95% CI Adjusted OR 95% CI
Sex
Male Ref Ref
Female 0.797 0.645–0.984* 0.835 0.670–1.034
Age
<65 years Ref Ref
≥65 years 1.521 1.209–1.913* 1.977 1.542–2.534*
Antibiotic prophylaxis
No Ref Ref
Yes 0.533 0.430–0.662* 0.459 0.366–0.575*
Types of surgery
Clean Ref Ref
Clean-contaminated 0.822 0.598–1.130 0.793 0.564–1.114
Contaminated 1.240 0.974–1.579 1.101 0.847–1.431
Dirty 1.482 0.961–2.285 1.367 0.879–2.127
Comorbidities
Neoplasm 1.637 1.217–2.203* 1.466 1.063–2.021*
Cardiovascular diseases 0.459 0.253–0.831* 0.372 0.197–0.702*
Notes: *Statistically significant; the 95% CI does not include a value of 1. 
Abbreviations: CI, confident interval; OR, odds ratio; Ref, reference.
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contaminated surgery. This could be explained that con-
taminated surgeries mostly involved gastrointestinal tract 
and deep organ which was the surgeon performing major 
procedures. On the other hand, dirty surgeries predomi-
nantly concerned cases of drainage of the abscess.
To the best of our knowledge, this is the first study to 
combine a comprehensive analysis of the impacts of dSSI on 
the hospitalization costs, and LoS. However, it has some 
limitations. First, we used data sourced from one academic 
hospital only and this hospital’s DBC coding for inpatient 
reimbursement, which may have led to the exclusion of some 
patients who received medication from the community or 
from general practitioners. Also, as our limitation of not 
analyzing the emergency or unplanned surgeries, there 
would be differences in outcomes, especially for the cost. 
Nevertheless, in the Netherlands, elective surgeries are pre-
dominant. Second, we applied a payer-based analytical per-
spective and did not consider indirect costs, specifically those 
associated with productivity losses. Third, this study did not 
cover the preferences of patients with dSSI and post-surgery, 
for example, regarding the quality of life outcomes.57 Fourth, 
in this study, we also found a few patients with bacteremia. 
However, numbers were too small to perform any analyses 
on the correlation between dSSI and bacteremia. Fifth, the 
generalization of the findings to other countries, for example, 
in the context of low-middle income countries may require 
adjustments relating to clinical-economic impacts and local 
healthcare systems. Moreover, other parameters in SSI pre-
vention bundles, such as shaving procedure, disinfections, 
operating room category, door opening frequency, were not 
taken into account in the analyses since the lack of relevant 
data. Overall, however, the findings of this study endorsed 
the implementation of infection prevention measures with 
quintessential AID stewardship within a hospital setting.
Conclusion
The impacts of dSSI manifest itself not only during the 
course of the disease but also in its consequences, as 
reflected in readmission rates, extended LoS, and addi-
tional costs. Identified independent variables for dSSI 
risk, notably patients’ older age and neoplasm comorbid-
ity, should intensively be monitored, and prophylactic 
antibiotics should definitely be considered in such cases. 
In addition, patients having dSSI and being 65 years and 
over both had an association with prolonged LoS. Further 
research should be directed towards evaluating patients’ 
characteristics in relation to dSSI impacts on an individual 
level rather than our group-based approach to allow a 
personalized strategy in infection prevention.
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